Alphatec Secures Exclusive Rights to OsteoAdapt® Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ATEC?
Source: Newsfilter
Alphatec Holdings Inc (ATEC) saw a significant decline of 19.38% as it crossed below its 5-day SMA, reflecting investor concerns following recent news.
The company has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft. This partnership is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure. OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its potential to revolutionize the bone regeneration market.
Despite the recent stock decline, the strategic partnership positions Alphatec to capitalize on a significant market opportunity in the U.S. spine surgery market, which exceeds $10 billion annually. The ongoing clinical trials and the expected commercialization of OsteoAdapt could drive future revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATEC
Wall Street analysts forecast ATEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATEC is 24.55 USD with a low forecast of 19.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 13.500
Low
19.00
Averages
24.55
High
28.00
Current: 13.500
Low
19.00
Averages
24.55
High
28.00
About ATEC
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. The Company is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. The Company's Organic Innovation Machine is focused on developing new approaches that integrate with its expanding Alpha InformatiX (AIX) Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include AIX, positioners, access systems, implants and fixation systems, and biologics. Its AIX product platform comprises its EOS imaging system and VEA alignment mobile application, its SafeOp Neural InformatiX System and its navigation-enabled robotics platform (Valence). It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alphatec Holdings Shares Show Oversold Signal
- Oversold Indicator: Alphatec Holdings Inc (Ticker: ATEC) hit an RSI of 28.6 during Tuesday's trading, indicating an oversold condition with shares dropping to a low of $15, suggesting that recent heavy selling may be nearing exhaustion.
- Market Comparison: Compared to the S&P 500 ETF's current RSI of 59.1, ATEC's oversold status could attract bullish investors looking for buying opportunities, indicating a potential shift in market sentiment.
- Historical Performance: Over the past 52 weeks, ATEC's stock has seen a low of $8.81 and a high of $23.29, with the latest trade at $15.06, highlighting the stock's volatility and potential for recovery.
- Investor Focus: As ATEC approaches oversold territory, investors may begin to look for rebound opportunities, particularly in the current market environment, seeking potential low-entry points.
See More
Alphatec (ATEC) Shares Surge 9.5% on Strong 2026 Revenue Outlook of $890 Million
- Significant Price Surge: Alphatec's shares soared 9.5% in the last trading session to close at $17.46, with trading volume significantly exceeding normal levels, indicating strong investor confidence in the company's future prospects.
- Strong Revenue Outlook: The company projects total revenue of $890 million for 2026, reflecting approximately 17% growth compared to 2025, suggesting sustained market demand that could drive further stock price increases.
- Acquisition of New Product Line: Alphatec announced the acquisition of exclusive U.S. distribution rights for Theradaptive's OsteoAdapt, a next-generation rhBMP-2 solution that will expand its procedural offerings and enhance its competitive position in the market.
- Optimistic Earnings Expectations: The upcoming quarterly report is expected to show earnings of $0.04 per share, representing a year-over-year increase of 117.4%, with revenues projected at $212.6 million, up 20.3% from the previous year, indicating strong profitability potential.
See More
Alphatec Holdings EVP Hunsaker Sells 32,584 Shares for $679,050
- Insider Sale: Craig E. Hunsaker, EVP of Alphatec Holdings, executed an open-market sale of 32,584 shares valued at $679,050 on December 10, 2025, which is significantly below his historical median sale size, indicating a potentially cautious outlook on the company's future.
- Ownership Analysis: This transaction represented 2.53% of Hunsaker's direct ownership, slightly below his historical median of 2.79%, suggesting a gradual reduction in his holdings that may impact shareholder confidence moving forward.
- Market Performance Comparison: While Alphatec's stock has surged 116.6% over the past year, significantly outperforming the S&P 500's 15% return, the company still faces challenges with profitability, necessitating careful risk assessment by investors.
- Strategic Partnership Outlook: The partnership with Theradaptive grants Alphatec exclusive rights to commercialize the OsteoAdapt spinal fusion technology, and if this translates into revenue growth, it could provide the company with a substantial competitive edge in the market.
See More
Alphatec (ATEC) Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment
- Strategic Partnership: ATEC has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft, which is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure.
- Technological Innovation: OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its potential to revolutionize the bone regeneration market and render traditional grafts and synthetic alternatives obsolete.
- Funding Initiative: Theradaptive has initiated a Series B funding round to support the completion of clinical studies and rapid scaling of its technology platform, which is expected to advance the OASIS pivotal trial and provide manufacturing scale-up for future commercialization.
- Market Opportunity: The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity, and ATEC's sales force is poised to maximize market penetration, thereby generating ongoing royalty revenue for Theradaptive.
See More
Alphatec (ATEC) Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Strategic Partnership
- Strategic Partnership: ATEC has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft, which is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure.
- Technological Innovation: OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its significant potential to transform the bone regeneration market.
- Funding Initiative: Theradaptive has initiated a Series B funding round to support the completion of clinical studies and rapid scaling of its technology platform, which is expected to accelerate the OASIS pivotal trial and provide necessary funding for future commercialization.
- Market Opportunity: The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity, and OsteoAdapt's targeted approach is poised to render traditional allograft and synthetic alternatives obsolete, driving sustained sales growth and market penetration for ATEC.
See More
Alphatec CEO Miles Patrick Sells 100,000 Shares for $2.1 Million
- Insider Selling: Alphatec Holdings CEO Miles Patrick sold 100,000 shares on Monday for approximately $2.1 million, representing 1.82% of his direct holdings, reducing his ownership to 5.14 million shares, indicating no loss of confidence in the company's future.
- Sustained Growth: In its most recent quarter, Alphatec reported revenue of $197 million, a 30% year-over-year increase, with surgical revenue climbing 31% to $177 million, reflecting strong demand and an increase in market share within the spine sector.
- Profitability Improvement: Adjusted EBITDA reached $26 million, expanding margins by over 800 basis points, while management raised full-year revenue guidance to approximately $760 million, underscoring confidence in sustained demand.
- Transparent Selling Plan: The sale was executed under a prearranged Rule 10b5-1 plan, representing a modest trim rather than a directional shift, with the CEO retaining over 5.1 million shares, maintaining alignment with shareholder interests.
See More
Alphatec Holdings Shares Show Oversold Signal
- Oversold Indicator: Alphatec Holdings Inc (Ticker: ATEC) hit an RSI of 28.6 during Tuesday's trading, indicating an oversold condition with shares dropping to a low of $15, suggesting that recent heavy selling may be nearing exhaustion.
- Market Comparison: Compared to the S&P 500 ETF's current RSI of 59.1, ATEC's oversold status could attract bullish investors looking for buying opportunities, indicating a potential shift in market sentiment.
- Historical Performance: Over the past 52 weeks, ATEC's stock has seen a low of $8.81 and a high of $23.29, with the latest trade at $15.06, highlighting the stock's volatility and potential for recovery.
- Investor Focus: As ATEC approaches oversold territory, investors may begin to look for rebound opportunities, particularly in the current market environment, seeking potential low-entry points.
See More
Alphatec (ATEC) Shares Surge 9.5% on Strong 2026 Revenue Outlook of $890 Million
- Significant Price Surge: Alphatec's shares soared 9.5% in the last trading session to close at $17.46, with trading volume significantly exceeding normal levels, indicating strong investor confidence in the company's future prospects.
- Strong Revenue Outlook: The company projects total revenue of $890 million for 2026, reflecting approximately 17% growth compared to 2025, suggesting sustained market demand that could drive further stock price increases.
- Acquisition of New Product Line: Alphatec announced the acquisition of exclusive U.S. distribution rights for Theradaptive's OsteoAdapt, a next-generation rhBMP-2 solution that will expand its procedural offerings and enhance its competitive position in the market.
- Optimistic Earnings Expectations: The upcoming quarterly report is expected to show earnings of $0.04 per share, representing a year-over-year increase of 117.4%, with revenues projected at $212.6 million, up 20.3% from the previous year, indicating strong profitability potential.
See More
Alphatec Holdings EVP Hunsaker Sells 32,584 Shares for $679,050
- Insider Sale: Craig E. Hunsaker, EVP of Alphatec Holdings, executed an open-market sale of 32,584 shares valued at $679,050 on December 10, 2025, which is significantly below his historical median sale size, indicating a potentially cautious outlook on the company's future.
- Ownership Analysis: This transaction represented 2.53% of Hunsaker's direct ownership, slightly below his historical median of 2.79%, suggesting a gradual reduction in his holdings that may impact shareholder confidence moving forward.
- Market Performance Comparison: While Alphatec's stock has surged 116.6% over the past year, significantly outperforming the S&P 500's 15% return, the company still faces challenges with profitability, necessitating careful risk assessment by investors.
- Strategic Partnership Outlook: The partnership with Theradaptive grants Alphatec exclusive rights to commercialize the OsteoAdapt spinal fusion technology, and if this translates into revenue growth, it could provide the company with a substantial competitive edge in the market.
See More
Alphatec (ATEC) Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment
- Strategic Partnership: ATEC has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft, which is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure.
- Technological Innovation: OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its potential to revolutionize the bone regeneration market and render traditional grafts and synthetic alternatives obsolete.
- Funding Initiative: Theradaptive has initiated a Series B funding round to support the completion of clinical studies and rapid scaling of its technology platform, which is expected to advance the OASIS pivotal trial and provide manufacturing scale-up for future commercialization.
- Market Opportunity: The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity, and ATEC's sales force is poised to maximize market penetration, thereby generating ongoing royalty revenue for Theradaptive.
See More
Alphatec (ATEC) Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Strategic Partnership
- Strategic Partnership: ATEC has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft, which is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure.
- Technological Innovation: OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its significant potential to transform the bone regeneration market.
- Funding Initiative: Theradaptive has initiated a Series B funding round to support the completion of clinical studies and rapid scaling of its technology platform, which is expected to accelerate the OASIS pivotal trial and provide necessary funding for future commercialization.
- Market Opportunity: The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity, and OsteoAdapt's targeted approach is poised to render traditional allograft and synthetic alternatives obsolete, driving sustained sales growth and market penetration for ATEC.
See More
Alphatec CEO Miles Patrick Sells 100,000 Shares for $2.1 Million
- Insider Selling: Alphatec Holdings CEO Miles Patrick sold 100,000 shares on Monday for approximately $2.1 million, representing 1.82% of his direct holdings, reducing his ownership to 5.14 million shares, indicating no loss of confidence in the company's future.
- Sustained Growth: In its most recent quarter, Alphatec reported revenue of $197 million, a 30% year-over-year increase, with surgical revenue climbing 31% to $177 million, reflecting strong demand and an increase in market share within the spine sector.
- Profitability Improvement: Adjusted EBITDA reached $26 million, expanding margins by over 800 basis points, while management raised full-year revenue guidance to approximately $760 million, underscoring confidence in sustained demand.
- Transparent Selling Plan: The sale was executed under a prearranged Rule 10b5-1 plan, representing a modest trim rather than a directional shift, with the CEO retaining over 5.1 million shares, maintaining alignment with shareholder interests.
See More
